5IF"VTUSBMJBO
i
S A T
UI&EJUJPO
i
M M U N
)BOECPPL
i
*NNVOJTBUJPO
O N
RECOGNITION AND TREATMEN...
16 downloads
1040 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
5IF"VTUSBMJBO
i
S A T
UI&EJUJPO
i
M M U N
)BOECPPL
i
*NNVOJTBUJPO
O N
RECOGNITION AND TREATMENT OF ANAPHYLAXIS Signs of anaphylaxis Anaphylaxis causes respiratory and/or cardiovascular signs or symptoms AND involves other organ systems such as skin or GI tract, with: t TLJOTJHOT TVDIBTUIFSBQJEEFWFMPQNFOUPGVSUJDBSJBMMFTJPOTPSFSZUIFNB t TJHOTPGVQQFSBJSXBZPCTUSVDUJPO TVDIBTIPBSTFOFTTBOETUSJEPS t JOEJDBUJPOTPGMPXFSBJSXBZPCTUSVDUJPO TVDIBTTVCKFDUJWFGFFMJOHTPGSFUSPTUFSOBMUJHIUOFTT EZTQOPFBPSXIFF[F t MJNQOFTTBOEQBMMPS XIJDIBSFTJHOTPGTFWFSFBOBQIZMBYJTJODIJMESFO t QSPGPVOEIZQPUFOTJPOJOBTTPDJBUJPOXJUIUBDIZDBSEJB BOEPSPUIFSTJHOTPGDBSEJPWBTDVMBS EJTUVSCBODF TVDIBTTJOVTUBDIZDBSEJBPSTFWFSFCSBEZDBSEJB t BCEPNJOBMDSBNQT EJBSSIPFBBOEPSWPNJUJOH Management of anaphylaxis t *GUIFQBUJFOUJTVODPOTDJPVT QMBDFIJNIFSPOUIFMFGUTJEFBOEQPTJUJPOUPLFFQUIFBJSXBZDMFBS*GUIFQBUJFOUJT DPOTDJPVT QMBDFTVQJOFJOAIFBEEPXOBOEGFFUVQQPTJUJPO VOMFTTUIJTSFTVMUTJOCSFBUIJOHEJóDVMUJFT t (JWFBESFOBMJOFCZJOUSBNVTDVMBSJOKFDUJPO TFFCFMPXGPSEPTBHF GPSBOZTJHOTPGBOBQIZMBYJTXJUISFTQJSBUPSZBOE PSDBSEJPWBTDVMBSTZNQUPNTPSTJHOT"MUIPVHIBESFOBMJOFJTOPUSFRVJSFEGPSHFOFSBMJTFEOPOBOBQIZMBDUJDSFBDUJPOT TVDIBTTLJOSBTIXJUIPVUPUIFSTJHOTPSTZNQUPNT BENJOJTUSBUJPOPGJOUSBNVTDVMBSBESFOBMJOFJTTBGF t *GUIFSFJTOPJNQSPWFNFOUJOUIFQBUJFOUTDPOEJUJPOCZNJOVUFT SFQFBUEPTFT PGBESFOBMJOFFWFSZNJOVUFTVOUJMJNQSPWFNFOUPDDVST t *GPYZHFOJTBWBJMBCMF BENJOJTUFSCZGBDFNBTLBUBIJHIøPXSBUF t $BMMGPSQSPGFTTJPOBMBTTJTUBODFBOEDBMMBOBNCVMBODF/FWFSMFBWFUIFQBUJFOUBMPOF t #FHJOFYQJSFEBJSSFTVTDJUBUJPOGPSBQOPFB DIFDLGPSBDFOUSBMQVMTF*GDFOUSBMQVMTF OPUQBMQBCMF DPNNFODFFYUFSOBMDBSEJBDNBTTBHF &$. t "MMDBTFTTIPVMECFBENJUUFEUPIPTQJUBMGPSGVSUIFSPCTFSWBUJPOBOEUSFBUNFOU &YQFSJFODFEQSBDUJUJPOFSTNBZDIPPTFUPVTFBOPSBMBJSXBZJGUIFBQQSPQSJBUFTJ[FJTBWBJMBCMF CVUJUTVTFJTOPUSPVUJOFMZSFDPNNFOEFEVOMFTT UIFQBUJFOUJTVODPOTDJPVT "OUJIJTUBNJOFTBOEPSIZESPDPSUJTPOFBSFOPUSFDPNNFOEFEGPSUIFFNFSHFODZNBOBHFNFOUPGBOBQIZMBYJT Adrenaline Dosage 5IFSFDPNNFOEFEEPTFPGBESFOBMJOFJTN-LHCPEZXFJHIU FRVJWBMFOUUP NHLHVQUPBNBYJNVNPGN-PSNH HJWFOCZEFFQJOUSBNVTDVMBSJOKFDUJPOJOUPUIFUIJHI notUIFEFMUPJESFHJPO "ESFOBMJOFmust not CFBENJOJTUFSFEJOUSBWFOPVTMZ "ESFOBMJOFDPOUBJOTNHPGBESFOBMJOFQFSN-PGTPMVUJPOJOBN-HMBTTWJBM 5IFVTFPGBESFOBMJOFJTSFDPNNFOEFECFDBVTFJUJTVOJWFSTBMMZBWBJMBCMF6TFBN- TZSJOHFUPJNQSPWFUIFBDDVSBDZPGNFBTVSFNFOUXIFOESBXJOHVQTNBMMEPTFT 5IFGPMMPXJOHUBCMFMJTUTUIFEPTFTPGBESFOBMJOFUPCFVTFEJGUIFFYBDUXFJHIUPGUIFJOEJWJEVBMJTOPULOPXO %PTFTPG POFJOPOFUIPVTBOE BESFOBMJOF -FTTUIBOZFBS
oN-
oZFBST BQQSPYLH
N-
oZFBST BQQSPYLH
N-
oZFBST BQQSPYLH
N-
oZFBST BQQSPYLH
N-
ZFBSTBOEPWFS PWFSLH
N-
oZFBST BQQSPYLH
N-
'PSNPSFEFUBJMFEJOGPSNBUJPO TFF4FDUJPO Adverse events following immunisation
CONTACT DETAILS FOR AUSTRALIAN, STATE AND TERRITORY GOVERNMENT HEALTH AUTHORITIES Australian Government health authorities Australian Government Health
State and Territory Government health authorities "VTUSBMJBO$BQJUBM5FSSJUPSZ *NNVOJTBUJPO&ORVJSZ-JOF
/FX4PVUI8BMFT
$POUBDUZPVSMPDBM1VCMJD)FBMUI6OJU GPVOEVOEFSA)FBMUIJOUIF8IJUF1BHFT
Northern Territory
Queensland
4PVUI"VTUSBMJB*NNVOJTBUJPO $PPSEJOBUJPO6OJU
IUUQXXXEITBHPWBVQFIT
Tasmania
or IUUQXXXEIITUBTHPWBVQVCMJDIFBMUIJNNVOJTBUJPOJOEFYIUNM
Victoria
IUUQXXXIFBMUIWJDHPWBVJNNVOJTBUJPO
8FTUFSO"VTUSBMJB
'PSJOGPSNBUJPOPOUIF"VTUSBMJBO$IJMEIPPE*NNVOJTBUJPO3FHJTUFSPSUPSFRVFTU BDIJMETJNNVOJTBUJPOIJTUPSZ QMFBTFSFGFSUP"QQFOEJY
What’s new? – Changes introduced in this edition of the Handbook See Chapter 1.1
COMPARISON OF THE EFFECTS OF DISEASES AND THE SIDE EFFECTS OF VACCINES DISEASE
EFFECT OF DISEASE
SIDE EFFECT OF VACCINE
%JQIUIFSJBoDPOUBHJPVTCBDUFSJBTQSFBECZESPQMFUT DBVTFTTFWFSFUISPBUBOECSFBUIJOHEJóDVMUJFT
"CPVUJOQBUJFOUTEJFT5IFCBDUFSJBSFMFBTFBUPYJO XIJDIDBOQSPEVDFOFSWFQBSBMZTJTBOEIFBSUGBJMVSF
%51BE5QBWBDDJOFoBCPVUJOIBTMPDBMJOøBNNBUJPOPS GFWFS#PPTUFSEPTFTPG%51BNBZPDDBTJPOBMMZCFBTTPDJBUFEXJUI FYUFOTJWFDJSDVNGFSFOUJBMTXFMMJOHPGUIFMJNC CVUUIJTSFTPMWFT DPNQMFUFMZXJUIJOBGFXEBZT4FSJPVTBEWFSTFFWFOUTBSFWFSZSBSF
)FQBUJUJT"oDPOUBHJPVTWJSVTTQSFBECZDPOUBDUPSJOHFTUJPO PGGBFDBMMZDPOUBNJOBUFEXBUFSGPPEPSUISPVHIDPOUBDUXJUI UIFGBFDBMNBUFSJBMPGBQFSTPOJOGFDUFEXJUIIFQBUJUJT"
+BVOEJDF ZFMMPXJOHPGUIFTLJOBOEFZFT
GFWFS BOPSFYJB OBVTFB "CPVUJOXJMMIBWFEJTDPNGPSUPSMPDBM WPNJUJOH IFQBUJD MJWFS QBJOBOENBMBJTF UJSFEOFTT *UNBZUBLF JOøBNNBUJPOBUUIFTJUFPGJOKFDUJPO VQUPNPOUIGPSQBUJFOUTUPSFDPWFSBOETPNFQBUJFOUTNBZSFRVJSF IPTQJUBMJTBUJPO:PVOHDIJMESFONBZOPUTIPXBOZTZNQUPNTCVUBSF TUJMMJOGFDUJPVT1BUJFOUTBSFJOGFDUJPVTVQUPXFFLTCFGPSFUIFPOTFU PGKBVOEJDFBOEGPSBQQSPYJNBUFMZXFFLBGUFSUIFKBVOEJDFBQQFBST
)FQBUJUJT#oWJSVTTQSFBENBJOMZCZCMPPE TFYVBMDPOUBDUPSGSPN "CPVUJODISPOJDDBSSJFSTXJMMEFWFMPQDJSSIPTJTPSMJWFSDBODFS NPUIFSUPOFXCPSOCBCZ DBVTFTBDVUFIFQBUJUJTPSDISPOJDDBSSJBHF
"CPVUJOXJMMIBWFJOKFDUJPOTJUFQBJOBOEJOXJMM IBWFGFWFS"OBQIZMBYJTPDDVSTJOBCPVUJO
)JCoDPOUBHJPVTCBDUFSJBTQSFBECZSFTQJSBUPSZ ESPQMFUT DBVTFTNFOJOHJUJT FQJHMPUUJUJT SFTQJSBUPSZ PCTUSVDUJPO
TFQUJDBFNJBBOEPTUFPNZFMJUJT
"CPVUJONFOJOHJUJTQBUJFOUTEJFTBOEBCPVU JOTVSWJWPSTIBTQFSNBOFOUCSBJOPSOFSWFEBNBHF "CPVUJOFQJHMPUUJUJTQBUJFOUTEJF
"CPVUJOIBTEJTDPNGPSUPSMPDBM JOøBNNBUJPO"CPVUJOIBTGFWFS
)VNBOQBQJMMPNBWJSVToWJSVTTQSFBENBJOMZWJBTFYVBMDPOUBDU
"CPVUJOPGDFSWJDBMDBODFSTXPSMEXJEFIBWFCFFO BTTPDJBUFEXJUI)17BOEJOXJUI)17
"CPVUJOXJMMIBWFQBJOBOEJOXJMMIBWF TXFMMJOHSFEOFTTBUUIFTJUFPGJOKFDUJPO7FSZPDDBTJPOBMMZ IFBEBDIF GFWFSBOEOBVTFBNBZPDDVS
*OóVFO[BoDPOUBHJPVTWJSVTTQSFBECZSFTQJSBUPSZESPQMFUT DBVTFTGFWFS NVTDMFBOEKPJOUQBJOT QOFVNPOJB
$BVTFTJODSFBTFEIPTQJUBMJTBUJPOJOUIFFMEFSMZ)JHISJTL HSPVQTJODMVEFUIFFMEFSMZ EJBCFUJDTBOEBMDPIPMJDT
"CPVUJOIBTMPDBMSFBDUJPOT(VJMMBJO#BSSÏ TZOESPNFPDDVSTJOBCPVUJONJMMJPO
.FBTMFToIJHIMZJOGFDUJPVTWJSVTTQSFBECZ ESPQMFUT DBVTFTGFWFS DPVHIBOESBTI
JODIJMESFOXJUINFBTMFTEFWFMPQTQOFVNPOJBBOE JOEFWFMPQTFODFQIBMJUJT CSBJOJOøBNNBUJPO 'PS FWFSZDIJMESFOXIPEFWFMPQNFBTMFTFODFQIBMJUJT EJFT BOEIBWFQFSNBOFOUCSBJOEBNBHF"CPVUJO EFWFMPQT441& CSBJOEFHFOFSBUJPO XIJDIJTBMXBZTGBUBM
"CPVUJOIBTEJTDPNGPSU MPDBMJOøBNNBUJPOPSGFWFS"CPVUJO EFWFMPQTBSBTIXIJDIJTOPOJOGFDUJPVT'FXFSUIBOJONJMMJPO SFDJQJFOUTNBZEFWFMPQFODFQIBMJUJT JOøBNNBUJPOPGUIFCSBJO
.FOJOHPDPDDBMJOGFDUJPOToCBDUFSJBTQSFBECZSFTQJSBUPSZ ESPQMFUT$BVTFTFQUJDBFNJB JOGFDUJPOPGUIFCMPPETUSFBN BOE NFOJOHJUJT JOGFDUJPOPGUIFUJTTVFTTVSSPVOEJOHUIFCSBJO
"CPVUJOQBUJFOUTEJFT0GUIPTFUIBUTVSWJWF JOIBTTFWFSF $POKVHBUFWBDDJOF"CPVUJOIBTMPDBMJOøBNNBUJPO TLJOTDBSSJOHPSMPTTPGMJNCT BOEJOIBTTFWFSFCSBJOEBNBHF GFWFS JSSJUBCJMJUZ BOPSFYJBPSIFBEBDIFT
.VNQToDPOUBHJPVTWJSVTTQSFBECZTBMJWB DBVTFT TXPMMFOOFDLBOETBMJWBSZHMBOETBOEGFWFS
JODIJMESFOEFWFMPQTFODFQIBMJUJTJONBMFT QBTUQVCFSUZEFWFMPQJOøBNNBUJPOPGUIFUFTUFT 0DDBTJPOBMMZ NVNQTDBVTFTJOGFSUJMJUZPSEFBGOFTT
JOWBDDJOFSFDJQJFOUTNBZEFWFMPQTXFMMJOHPGUIFTBMJWBSZ HMBOETJONJMMJPOSFDJQJFOUTEFWFMPQTNJMEFODFQIBMJUJT
1FSUVTTJToDPOUBHJPVTCBDUFSJBTQSFBECZSFTQJSBUPSZESPQMFUT DBVTFTXIPPQJOHDPVHIBOEWPNJUJOHMBTUJOHVQUPNPOUIT
"CPVUJOXIPPQJOHDPVHIQBUJFOUTVOEFSUIFBHF PGNPOUITEJFTGSPNQOFVNPOJBPSCSBJOEBNBHF
%51BE5QBWBDDJOFoBCPVUJOIBTMPDBMJOøBNNBUJPOPS GFWFS#PPTUFSEPTFTPG%51BNBZPDDBTJPOBMMZCFBTTPDJBUFEXJUI FYUFOTJWFDJSDVNGFSFOUJBMTXFMMJOHPGUIFMJNC CVUUIJTSFTPMWFT DPNQMFUFMZXJUIJOBGFXEBZT4FSJPVTBEWFSTFFWFOUTBSFWFSZSBSF
1OFVNPDPDDBMJOGFDUJPOToCBDUFSJBTQSFBECZSFTQJSBUPSZESPQMFUT "CPVUJONFOJOHJUJTQBUJFOUTEJFT DBVTFTTFQUJDBFNJB NFOJOHJUJTBOEPDDBTJPOBMMZPUIFSJOGFDUJPOT
W1$7oBCPVUJOIBTMPDBMSFBDUJPOPSGFWFS
1PMJPoDPOUBHJPVTWJSVTTQSFBECZGBFDFTBOETBMJWB DBVTFT GFWFS IFBEBDIFBOEWPNJUJOHBOENBZQSPHSFTTUPQBSBMZTJT
8IJMFNBOZJOGFDUJPOTDBVTFOPTZNQUPNT BCPVU JOIPTQJUBMJTFEQBUJFOUTEJFTBOEJOQBUJFOUT XIPTVSWJWFJTQFSNBOFOUMZQBSBMZTFE
-PDBMSFEOFTT QBJOBOETXFMMJOHBUUIFTJUFPGJOKFDUJPOBSF DPNNPO6QUPJOIBTGFWFS DSZJOH BOEEFDSFBTFEBQQFUJUF
3PUBWJSVToWJSVTTQSFBECZGBFDBMPSBMSPVUF DBVTFTHBTUSPFOUFSJUJTXIJDIDBOCFTFWFSF
*ODIJMESFO ZFBSTPGBHF SPUBWJSVTJOGFDUJPOTJO"VTUSBMJB BDDPVOUGPSBQQSPYJNBUFMZIPTQJUBMJTBUJPOTFWFSZZFBS BQQSPYJNBUFMZDIJMESFOWJTJUB(1BOEBQQSPYJNBUFMZ DIJMESFOSFRVJSFBO&NFSHFODZ%FQBSUNFOUWJTJU*MMOFTT NBZSBOHFGSPNNJME XBUFSZEJBSSIPFBPGMJNJUFEEVSBUJPOUP TFWFSFEFIZESBUJOHEJBSSIPFBBOEGFWFSXIJDIDBOSFTVMUJOEFBUI
oJOWBDDJOFSFDJQJFOUTNBZEFWFMPQEJBSSIPFBPS WPNJUJOHJOUIFXFFLGPMMPXJOHWBDDJOFBENJOJTUSBUJPO
3VCFMMBoDPOUBHJPVTWJSVTTQSFBECZESPQMFUT DBVTFT GFWFS SBTIBOETXPMMFOHMBOET CVUDBVTFTTFWFSF NBMGPSNBUJPOTJOCBCJFTPGJOGFDUFEQSFHOBOUXPNFO
"CPVUJOQBUJFOUTEFWFMPQBSBTIBOEQBJOGVMTXPMMFOHMBOET JOBEPMFTDFOUTBOEBEVMUTIBWFQBJOGVMKPJOUT JO EFWFMPQTUISPNCPDZUPQFOJB CSVJTJOHPSCMFFEJOH JO EFWFMPQTJOøBNNBUJPOPGUIFCSBJO JOCBCJFTJOGFDUFEEVSJOH UIFöSTUXFFLTBGUFSDPODFQUJPOXJMMIBWFBNBKPSDPOHFOJUBM BCOPSNBMJUZ JODMVEJOHEFBGOFTT CMJOEOFTTPSIFBSUEFGFDUT
"CPVUJOIBTEJTDPNGPSU MPDBMJOøBNNBUJPO PS GFWFS"CPVUJOIBTTXPMMFOHMBOET TUJòOFDL PSKPJOU QBJOT"CPVUJOIBTBSBTI XIJDIJTOPOJOGFDUJPVT 5ISPNCPDZUPQFOJB CSVJTJOHPSCMFFEJOH PDDVSTBGUFS BöSTUEPTFPG..3BUBSBUFPGBCPVUJO
5FUBOVToDBVTFECZUPYJOPGCBDUFSJBJOTPJM DBVTFT QBJOGVMNVTDMFTQBTNT DPOWVMTJPOT MPDLKBX
"CPVUJOQBUJFOUTEJFT5IFSJTLJT HSFBUFTUGPSUIFWFSZZPVOHPSPME
%51BE5QBWBDDJOFoBCPVUJOIBTMPDBMJOøBNNBUJPOPS GFWFS#PPTUFSEPTFTPG%51BNBZPDDBTJPOBMMZCFBTTPDJBUFEXJUI FYUFOTJWFDJSDVNGFSFOUJBMTXFMMJOHPGUIFMJNC CVUUIJTSFTPMWFT DPNQMFUFMZXJUIJOBGFXEBZT4FSJPVTBEWFSTFFWFOUTBSFWFSZSBSF
7BSJDFMMB DIJDLFOQPY oIJHIMZDPOUBHJPVTWJSVT DBVTFT MPXHSBEFGFWFSBOEWFTJDVMBSSBTI3FBDUJWBUJPOPGUIF WJSVTMBUFSJOMJGFDBVTFTIFSQFT[PTUFS TIJOHMFT
JOQBUJFOUTEFWFMPQFODFQIBMJUJT CSBJOJOøBNNBUJPO "CPVUJOQBUJFOUTEJF*OGFDUJPOEVSJOHQSFHOBODZDBO SFTVMUJODPOHFOJUBMNBMGPSNBUJPOTJOUIFCBCZ0OTFUPGJOGFDUJPO JOUIFNPUIFSGSPNEBZTCFGPSFUPEBZTBGUFSEFMJWFSZSFTVMUTJO TFWFSFJOGFDUJPOJOUIFOFXCPSOCBCZJOVQUPPOFUIJSEPGDBTFT
"CPVUJOIBTBMPDBMSFBDUJPOPSGFWFS"NJMEWBSJDFMMB MJLFSBTINBZEFWFMPQJOoJOSFDJQJFOUT
W117oBCPVUJOIBTBMPDBMSFBDUJPO
ADVERSE EVENTS FOLLOWING IMMUNISATION Commonly observed adverse events following immunisation with vaccines used in the National Immunisation Program (NIP) schedule and what to do about them The following information can be photocopied and given as post-vaccination advice. All the common adverse events following immunisation are usually mild and transient and treatment is not usually required. If the adverse event following immunisation is severe or persistent, or if you are worried about yourself or your child’s condition, see your doctor or immunisation clinic nurse as soon as possible or go to a hospital. Adverse events may be reported via ADRAC, State and Territory Health Authorities or via immunisation service providers. Diphtheria-tetanus-pertussis (acellular) DTPa-containing vaccines and dTpa (adolescent/adult) vaccines
Haemophilus influenzae type b vaccine (Hib)
Hepatitis A vaccine (HepA) (Indigenous children NT, QLD, SA, WA)
Hepatitis B vaccine (HepB)
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t -PXHSBEFUFNQFSBUVSF GFWFS
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t -PXHSBEFUFNQFSBUVSF GFWFS
t -PXHSBEFUFNQFSBUVSF GFWFS
t -PXHSBEFUFNQFSBUVSF GFWFS
In children the following may also occur: t *SSJUBCMF DSZJOH VOTFUUMFEBOE generally unhappy t %SPXTJOFTTPSUJSFEOFTT Human papillomavirus vaccine (HPV)
Influenza vaccine
Measles-mumps-rubella vaccine (MMR)
Meningococcal C conjugate vaccine (MenCCV)
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t %SPXTJOFTTPSUJSFEOFTT
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t *SSJUBCMF DSZJOH VOTFUUMFEBOE generally unhappy
Seen 7–10 days after vaccination:
t -PTTPGBQQFUJUF
t 5FNQFSBUVSF GFWFS DBOCF 0C) MBTUJOHoEBZT GBJOUSFESBTI OPU infectious), head cold and/or runny nose, cough and/or puffy eyes
t )FBEBDIF VTVBMMZPCTFSWFE in adolescents/adults)
t %SPXTJOFTTPSUJSFEOFTT
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t -PXHSBEFUFNQFSBUVSF GFWFS
t .JMEIFBEBDIF t .JMEOBVTFB
t .VTDMFBDIFT t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed) t -PXHSBEFUFNQFSBUVSF GFWFS
t 4XFMMJOHPGTBMJWBSZHMBOET
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t -PXHSBEFUFNQFSBUVSF GFWFS
Pneumococcal vaccines (conjugate 7vPCV and polysaccharide 23vPPV)
Inactivated poliomyelitis vaccine (IPV) and IPV-containing vaccines
Rotavirus vaccine
Varicella vaccine (VV)
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t .VTDMFBDIFT
t 7PNJUJOHBOEEJBSSIPFBDBOPDDVSVQ to 7 days following vaccination
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed) t -PXHSBEFUFNQFSBUVSF GFWFS
t -PDBMJTFEQBJO SFEOFTTBOE swelling at injection site
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t 0DDBTJPOBMMZJOKFDUJPOTJUFOPEVMF NBZ last many weeks (no treatment needed)
t 5FNQFSBUVSF GFWFS DBOCF 0C)
t -PXHSBEFUFNQFSBUVSF GFWFS
Seen 5–26 days after vaccination: t 1VTUVMBSSBTI oMFTJPOT VTVBMMZBUJOKFDUJPO site, occasionally other parts of the body
Key to table DTPa
diphtheria-tetanus-pertussis acellular (infant/child formulation)
IPV
inactivated poliomyelitis vaccine
dTpa
diphtheria-tetanus-pertussis acellular (adolescent/adult formulation)
MenCCV
meningococcal C conjugate vaccine
HepA
hepatitis A vaccine
MMR
measles-mumps-rubella vaccine
HepB
hepatitis B vaccine
7vPCV
7-valent pneumococcal conjugate vaccine
Hib
Haemophilus influenzaeUZQFCWBDDJOF 1310.1PS1315
23vPPV
WBMFOUQOFVNPDPDDBMQPMZTBDDIBSJEFWBDDJOF
HPV
human papillomavirus vaccine
Rotavirus
rotavirus vaccine
Influenza
influenza or flu vaccine
VV
varicella vaccine
What to do to manage injection site discomfort .BOZWBDDJOFJOKFDUJPOTNBZSFTVMUJOTPSFOFTT SFEOFTT JUDIJOH TXFMMJOHPSCVSOJOHBUUIFJOKFDUJPOTJUFGPSUPEBZT1BSBDFUBNPMNJHIUCFSFRVJSFEUPFBTFUIF EJTDPNGPSU4PNFUJNFTBTNBMM IBSEMVNQNBZQFSTJTUGPSTPNFXFFLTPSNPOUIT5IJTTIPVMEOPUCFPGDPODFSOBOESFRVJSFTOPUSFBUNFOU Managing fever after immunisation (JWFFYUSBøVJETUPESJOL%POPUPWFSESFTTBOJOGBOUJGIPU"MUIPVHIUIFSPVUJOFVTFPGQBSBDFUBNPMBUUIFUJNFPGWBDDJOBUJPOJTOPMPOHFSOFDFTTBSZ JUNBZCFSFRVJSFEJG GPSFYBNQMF BOJOGBOUPSDIJMEIBTBIJHIGFWFSGPMMPXJOHWBDDJOBUJPO5IFEPTFPGQBSBDFUBNPMJTNHLHPGQBSBDFUBNPMMJRVJE VQUPBNBYJNVNEBJMZEPTFPGNHLHQFSEBZ
Copyright © Australian Government 2008 Paper-based publication This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part may be reproduced by any process without written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney-General’s Department, Robert Garran Offices, National Circuit, Canberra, ACT, 2600 or posted at: http://www.ag.gov.au/cca ISBN 1-74186-483-6 Electronic documents This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use, or use within your organisation. Apart from any use as permitted under the Copyright Act 1968, all other rights are reserved. Requests for further authorisation should be directed to the Commonwealth Copyright Administration, Attorney-General’s Department, Robert Garran Offices, National Circuit, Canberra, ACT, 2600 or posted at: http://www.ag.gov.au/cca Online ISBN: 1-74186-484-4 Publication Approval Number: 2923
Disclaimer While every effort has been made to check drug dosage recommendations in this Handbook, it is still possible that errors have been missed. Furthermore, dosage recommendations are continually being revised and new adverse events recognised. Trade names used in this publication are for identification purposes only. Their use does not imply endorsement of any particular brand of drug or vaccine. This Handbook is a general guide to appropriate practice subject to clinician’s judgement in each individual case. It is designed to provide information to assist decision making using the best information available at date of National Health and Medical Research Council approval (11 October 2007). The Australian Government Department of Health and Ageing does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information.
The NHMRC The National Health and Medical Research Council (NHMRC) is Australia’s leading funding body for health and medical research. The NHMRC also provides the government, health professionals and the community with expert and independent advice on a range of issues that directly affect the health and well being of all Australians. The NHMRC provided support to this project through its Guidelines Assessment Register (GAR) process. The GAR consultant on this project was Biotext Pty Ltd. These Guidelines, apart from Chapters 3.7 and 3.9, were approved by the Chief Executive Officer of the NHMRC under Section 14A of the National Health and Medical Research Council Act, 1992 on 17 July 2007. The remaining two chapters were approved on 11 October 2007.
The ATAGI The Australian Technical Advisory Group on Immunisation (ATAGI) was established by the then Minister for Health and Family Services in 1998 to provide expert technical and scientific advice on the Immunise Australia Program and to work cooperatively with the NHMRC on issues such as the The Australian Immunisation Handbook.
The Handbook This Handbook is published approximately every three years but changes to the recommendations or schedule may occur between publications. The Handbook and any changes between publications are available on the website: www.immunise.health.gov.au. This hardcopy version of the Handbook does not contain any references — these are available on the electronic version. Ninth Edition January 2008
ii The Australian Immunisation Handbook 9th Edition
PREFACE The 9th edition of The Australian Immunisation Handbook was prepared by the Australian Technical Advisory Group on Immunisation of the Australian Government Department of Health and Ageing.
Members of the Australian Technical Advisory Group on Immunisation Chair Professor Terry Nolan, Paediatrician and Epidemiologist and Head, School of Population Health, The University of Melbourne, VIC.
Members Ms Jenny Bourne, Assistant Secretary, Targeted Prevention Programs Branch, Population Health Division, Australian Government Department of Health and Ageing, ACT. Ms Sue Campbell-Lloyd, Manager, Immunisation Unit, AIDS/Infectious Diseases Branch, NSW Health, NSW. Dr Grahame Dickson, Medical Officer, Drug Safety and Evaluation Branch, Therapeutic Goods Administration, Australian Government Department of Health and Ageing, ACT. Dr Nicole Gilroy, Staff Specialist, Infectious Diseases, Westmead Hospital, Centre for Infectious Diseases and Microbiology, Western Sydney Area Health Service, and Infectious Diseases Physician, BMT Network, NSW. Dr Jeffrey Hanna, Medical Director, Communicable Disease Control, Tropical Population Health Unit, Queensland Health, QLD. Ms Jenni Howlett, State President, Child Health Association, TAS. Clinical Professor David Isaacs, Paediatrician, Department of Immunology and Infectious Diseases, The Children’s Hospital at Westmead, NSW. Ms Ann Kempe, Surveillance Manager, CCRE in Child and Adolescent Immunisation, Murdoch Children’s Research Institute, Royal Children’s Hospital, VIC. Dr Rosemary Lester, Assistant Director, Public Health Branch, Communicable Disease Control Unit, Department of Human Services, VIC. Professor Peter McIntyre, Professor of Paediatrics and Preventive Medicine, The University of Sydney, and Director, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children’s Hospital at Westmead, NSW. Dr Joanne Molloy, General Practitioner, Medical Officer of Health, City of Greater Geelong, and Immunisation Program Manager, GP Association of Geelong, VIC. Associate Professor Michael Nissen, Director of Infectious Diseases and Clinical Microbiologist, Unit Head of Queensland Paediatric Infectious Disease Laboratory, and Associate Professor in Biomolecular, Biomedical Science and Health, Royal Children’s Hospital, QLD.
Preface iii
Dr Rod Pearce, General Practitioner, Medical Officer of Health, Eastern Health Authority, Adelaide and GP Immunisation Advisor, Adelaide Central and Eastern Division of General Practice, SA. Dr Peter Richmond, Senior Lecturer, University of Western Australia, School of Paediatrics and Child Health, and General Paediatrician and Paediatric Immunologist, Princess Margaret Hospital for Children, WA. Dr Sue Skull, Paediatrician, Clinical Epidemiologist and Public Health Physician, and Senior Lecturer, Department of Paediatrics, The University of Melbourne, VIC.
Secretary Ms Letitia Toms, Director, Immunisation Policy Section, Targeted Prevention Programs Branch, Population Health Division, Australian Government Department of Health and Ageing, ACT.
Secretariat support, Australian Technical Advisory Group on Immunisation Ms Brigid Dohnt, Mrs Claire Kellie, Ms Jacinta Holdway, Mr John Mohoric, Ms Sally Warild.
Technical Editors Dr Jane Jelfs, Immunisation Handbook and Policy Support Coordinator, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children’s Hospital at Westmead, NSW. Dr Kristine Macartney, Senior Research Fellow, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children’s Hospital at Westmead, NSW.
Handbook Technical Support Ms Catherine King, Information Manager, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children’s Hospital at Westmead, NSW. Ms Donna Armstrong, Communications Officer, National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney and The Children’s Hospital at Westmead, NSW.
Technical Writers Dr Julia Brotherton, Dr Tony Gherardin, Ms Heather Gidding, Dr Kate Hale, Dr Jeffrey Hanna, Ms Anita Heywood, Professor David Isaacs, Dr Jane Jelfs, Ms Ann Kempe, Dr Kristine Macartney, Professor Peter McIntyre, Mr Robert Menzies, Dr Joanne Molloy, Dr Helen Quinn, Dr Yashwant Sinha, Dr Nicholas Wood.
iv The Australian Immunisation Handbook 9th Edition
Acknowledgments Associate Professor Ross Andrews
Dr Amanda Leach
Professor Graeme Barnes
Dr Julie Leask
Professor Richard Benn
Professor Raina MacIntyre
Associate Professor Beverley Biggs
Professor Barrie Marmion
Professor Julie Bines
Dr Helen Marshall
Dr Ian Boyd
Dr Brad McCall
Professor Anthony Brown
Dr Treasure McGuire
Professor Margaret Burgess
Ms Cathlyn McInnes
Dr Jim Buttery
Dr Moira McKinnon
Professor Jonathan Carapetis
Dr Jodie McVernon
Dr Louise Causer
Dr Ann Mijch
Ms Patricia Coward
Professor Kim Mulholland
Dr Angela Dean
Dr Neil Parker
Dr Ki Douglas
Ms Karen Peterson
Ms Barbara Eldred
Ms Susie Prest
Mr Lloyd Ellis
Professor William Rawlinson
Professor Kevin Forsyth
Dr Jenny Royle
Professor Lyn Gilbert
Dr Tilman Ruff
Dr Mike Gold
Ms Andrea Schaffer
Dr Robert Hall
Dr Rosalie Schultz
Dr Alan Hampson
Dr Christine Selvey
Professor Mark Harris
Dr Linda Selvey
Ms Trish Harris
Ms Barbara Steadman
Dr Bronwen Harvey
Dr John Sullivan
Dr Bob Kass
Mr Sean Tarrant
Dr Heath Kelly
Dr Diana Thomas
Dr Vicki Krause
Dr Bruce Thorley
Dr Andrew Langley
Dr Melanie Wong
Dr Glenda Lawrence
Dr Margaret Young
Preface v
Contents PART 1: VACCINATION PROCEDURES
1
Introduction to The Australian Immunisation Handbook
1
1.1 What’s new?
3
1.2 An overview of vaccination – preface to Chapters 1.3–1.5
7
1.3 Pre-vaccination procedures 1.3.1 Preparing an anaphylaxis response kit 1.3.2 Effective cold chain: transport, storage and handling of vaccines 1.3.3 Valid consent 1.3.4 Pre-vaccination screening 1.3.5 Catch-up
8 8 8 12 14 21
1.4 Administration of vaccines 1.4.1 Occupational health and safety issues 1.4.2 Equipment for vaccination 1.4.3 Route of administration 1.4.4 Preparation for vaccine administration 1.4.5 Vaccine injection techniques 1.4.6 Recommended injection sites 1.4.7 Positioning for vaccination 1.4.8 Identifying the injection site 1.4.9 Administering multiple vaccine injections at the same visit
39 39 39 41 43 44 45 47 51 56
1.5 Post-vaccination procedures 1.5.1 Immediate after-care 1.5.2 Adverse events following immunisation 1.5.3 Documentation of vaccination 1.5.4 The Australian Childhood Immunisation Register
58 58 58 66 67
PART 2: Vaccination for special risk groups
70
2.1 Vaccination for Aboriginal and Torres Strait Islander people
70
2.2 Vaccination for international travel
75
2.3 Groups with special vaccination requirements 2.3.1 Vaccination of children who have had a serious adverse event following immunisation (AEFI) 2.3.2 Vaccination of women planning pregnancy, pregnant or breastfeeding women, and preterm infants 2.3.3 Vaccination of individuals with impaired immunity due to disease or treatment 2.3.4 Vaccination of recent recipients of normal human immunoglobulin 2.3.5 Vaccination of patients following receipt of other blood products including blood transfusions 2.3.6 Vaccination of patients with bleeding disorders 2.3.7 Vaccination before or after anaesthesia/surgery 2.3.8 Vaccination of those at occupational risk
84
vi The Australian Immunisation Handbook 9th Edition
84 84 90 102 102 104 104 104
2.3.9 2.3.10 2.3.11 2.3.12
Vaccination of immigrants to Australia Vaccination of inmates of correctional facilities Vaccination of men who have sex with men Vaccination of injecting drug users
PART 3: Vaccines listed by disease
108 108 108 109
110
3.1 Australian bat lyssavirus infection and rabies
110
3.2 Cholera
120
3.3 Diphtheria
124
3.4 Haemophilus influenzae type b (Hib)
131
3.5 Hepatitis A
139
3.6 Hepatitis B
149
3.7 Human papillomavirus
164
3.8 Immunoglobulin preparations
175
3.9 Influenza
184
3.10 Japanese encephalitis
195
3.11 Measles
201
3.12 Meningococcal disease
213
3.13 Mumps
223
3.14 Pertussis
227
3.15 Pneumococcal disease
240
3.16 Poliomyelitis
251
3.17 Q fever
257
3.18 Rotavirus
265
3.19 Rubella
274
3.20 Smallpox
283
3.21 Tetanus
288
3.22 Tuberculosis
297
3.23 Typhoid
303
3.24 Varicella
309
3.25 Yellow fever
322
3.26 Zoster (herpes zoster)
329
Contents vii
Appendix 1: Contact details for Australian, State and Territory Government health authorities and communicable disease control
332
Appendix 2: Handbook development
334
Appendix 3: Products registered in Australia but not currently available
339
Appendix 4: Components of vaccines used in the National Immunisation Program
340
Appendix 5: Commonly asked questions about vaccination
344
Appendix 6: Definitions of adverse events following immunisation
360
Appendix 7: Glossary of technical terms
364
Appendix 8: List of commonly used abbreviations
369
Appendix 9: Dates when vaccines became available in Australia
372
Appendix 10: Summary table – procedures for a vaccination encounter
375
Index
378
viii The Australian Immunisation Handbook 9th Edition
Index of Tables Table 1.3.1: Pre-vaccination screening checklist
16
Table 1.3.2: Responses to relevant conditions or circumstances identified by the pre-vaccination screening checklist
17
Table 1.3.3: Live attenuated parenteral and oral vaccines
20
Table 1.3.4: False contraindications to vaccination
21
Table 1.3.5: Number of vaccine doses that should have been administered by the current age of the child (table to be used in conjunction with Catch-up Worksheet)
28
Table 1.3.6: Minimum dose intervals for NIP vaccines for children
